rPA Vaccine Development Highlights: Year 1

• Worldwide rights licensed from USAMRIID

• Preclinical development completed

• Challenge studies completed in rabbit and monkey studies; pivotal studies planned

• cGMP manufacture of clinical supplies

• IND approved

• Results submitted from Phase 1, dose ascending study, with AVA comparison

• Feasibility plan for manufacture of 25 million dose stockpile delivered

• Product liability insurance secured

Previous slide

Next slide

Back to first slide

View graphic version